The genetic component of some cases of dementia has long been recognised. In 1987 a locus on chromosome 21 was found to be associated with a very aggressive form of Alzheimer's disease with a strong familial transmission (autosomal dominant inheritance).' Four years later the defect was identified in a point mutation of the amyloid precursor protein encoding gene.2 Members of families carrying the mutation always developed Alzheimer's disease by about 65 years of age, and members not carrying the mutation did not. The very high penetrance of the mutated trait pointed to amyloid as the potential causative agent of the disease' and suggested the potential use of searching for this mutation in the diagnostic clinical setting.3 In subsequent years, the search for other cases of dementia with a genetic component was disappointing. The genetics of some familial dementias were described. These dementias included familial prion diseases,4 hereditary cerebral haemorrhages with amyloidosis, Dutch type,5 chromosome 17 and chromosome 3 linked forms of frontal lobe dementia,67 and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).8 The genetic defect of Huntington's disease was localised on chromosome 4,9 and some more pathogenic amyloid precursor protein mutations were discovered, usually with very high penetrance.'0-"3 However, the low frequency of these cases in the overall demented population'4 led clinicians working on dementia to consider the genetic component to be of little practical relevance. The discovery in 1993 of the association between the highly prevalent late onset form of Alzheimer's disease and the E4 allele of the apolipoprotein E gene (APOE),"5 16 and in 1995 between some families with autosomal dominant Alzheimer's disease and presenilin-1 (PS1) and presenilin-2 (PS2) mutated genes on chromosomes 14 and 1 kindled new interest. '7 18 Diagnostic kits for APOE genotyping are now commercially available, the presenilin genes have been fully sequenced, the proteins synthesised, and clues to their physiological action are increasingly being discovered. However, the usefulness of these new discoveries in daily clinical practice is often unclear and deserves critical discussion.
This review considers the genetic issues related to Alzheimer's disease as these are the most prevalent in clinical practice, have the largest body of literature, and are those with the most recent and promising developments. Guidelines on genetic testing in Huntington's disease are well established and can be found elsewhere. '9 20 It is emphasised that the conclusions of this paper should be treated with caution due to the rapid evolution of this field of medicine.
Genetic pathogenic mutations and genetic risk factors: biology and epidemiology Genetic studies in dementia are relevant to the understanding of the pathogenesis of the disease, and as clinical tools for diagnosis and prognosis. To understand the theoretical and practical implications of such studies, a brief introduction on amyloid precursor protein, presenilin mutations, and genetic risk factors may be useful.
Mutations of amyloid precursor protein have a very high penetrance, nearly 100%21 and PS1 mutations are similar, '7-22 suggesting that the encoded proteins might be very close to the core of the biochemical trigger starting the cascade23 that leads to neuronal degeneration and death. Presenilins might cause Alzheimer's disease by increasing amyloid deposition in the brain," 24-27 further underlining the central role of amyloid in the pathogenesis of Alzheimer's disease. More indirect evidence points to an effect on tangle formation. 28 29 The search for mutated genes in autosomal dominant Alzheimer's disease has a theoretical basis in the one gene, one disease model, assuming that the Alzheimer's disease "trait" comprises several subtraits, each influenced by a single gene. 30 It is likely that mutations of amyloid precursor protein, PSI, and PS2 genes are responsible for a very large proportion of all cases of autosomal dominant Alzheimer's disease,31 amyloid precursor protein accounting for 2%-3%, PS1 for about 50%-80%, and PS2 mutations for the remaining 15%-20% (Volga-German kindred). However, autosomal dominant Alzheimer's disease is very rare in practice. What is not rare (at least 25% of all cases of Alzheimer's disease)32 33 is a history of dementia in one first degree relative.343 This criterion is much less stringent than those underlying autosomal dominant inheritance and defines what is often referred to as "familial Alzheimer's disease". Unfortunately, this term has also been given to some kindreds with autosomal dominant Alzheimer's disease. 1 2 10 12 14 17 33 36-38 That there is a basic difference between autosomal dominant Alzheimer's disease and familial Alzheimer's disease is supported by the finding that in clinical series in which familial Alzheimer's disease is frequent but autosomal dominant Alzheimer's disease is rare, the frequencies of amyloid precursor protein, PS1, and PS2 mutations are low. 14 3943 The search for genetic or environmental risk factors in dementia and Alzheimer's disease has a long history. 44 The discovery of the association of the £4 allele of APOE with Alzheimer's disease rightly kindled great interest as for the first time a highly prevalent and easily detectable factor was consistently found related to 84 Therefore, the usefulness of a routine search for the known mutations in patients with familial Alzheimer's disease seems limited.
Having a family history of Alzheimer's disease on the other hand, does seem to increase the risk of developing the disease,85 which points to the effect of a genetic factor. Although the genetic factor responsible for this increased susceptibility has not yet been identified, it has been suggested that APOE might account for the familial aggregation.51 86 This view is supported by the finding that family history for dementia is more often reported by Alzheimer's disease e4 carriers than non-E4 carriers.5' Sporadic Alzheimer's disease The E4 allele is more common in patients with sporadic late onset Alzheimer's disease than in elderly controls (about 40% v 10%-15%).16 This finding, together with the increased frequency of the e4 allele in familial late onset Alzheimer's disease, suggests that the detection of an e4 allele in a demented patient might increase the likelihood of the patient having Alzheimer's disease. On these grounds, APOE genotyping has been thought to increase the accuracy of diagnosis of Alzheimer's disease.87 88 Roses has argued that the detection of an e4/E4 genotype in a demented patient confers a 95% probability of Alzheimer's disease.88 However, this is true only if the frequency of the E4 allele in the non-Alzheimer's disease dementias is not increased. Some authors have reported increased e4 allele frequency in Lewy body dementias89 90 and vascular dementias.3355 If this is the case, the role of APOE genotyping in the diagnosis of Alzheimer's disease might be less important than previously claimed,91 and the value of testing might be disputed.
The most recent guidelines on the use of APOE genotyping in dementia cautiously accept the possibility that APOE genotyping might be a useful confirmatory diagnostic test, but do not recommend its use until fuller epidemiological data are available. The clinical meaning of APOE genotyping as a predictor of development of disease is less clear. It has been shown with PET that elderly non-demented e4/E4 subjects and relatives of patients with Alzheimer's disease carrying the e4 allele have cerebral metabolic defects similar to those of patients with Alzheimer's disease.9495 Furthermore, nondemented elderly E4 carriers have 2-2 to 3-7-fold greater risk of developing Alzheimer's disease.5255 These findings contrast with those obtained from cross sectional clinical series indicating a much closer association of the e4 allele with having Alzheimer's disease (risk of 6-2, 95% confidence interval 4 9 to 7-8 in a large series of combined studies).47 This means that the high frequency of the E4 allele in Alzheimer's disease is only partly due to the increased risk given by the E4 allele. The remainder might be due to an enrichment of e4 in the Alzheimer's disease population due to longer duration of disease in Alzheimer's disease e4 allele carriers,9698 or to impoverishment of the E4 allele in the non-Alzheimer's elderly population due to selective cardiovascular mortality in e4 allele carriers,99100 or both.
It must be emphasised that currently available guidelines strongly advise against APOE genotyping aimed at disease prediction in asymptomatic subjects. 92 93 GENETIC TESTING AT THE POPULATION LEVEL Genetic testing at the population level is aimed at selecting large groups of at risk or affected people for primary or secondary prophylaxis. Whatever estimate of the strength of the association between the E4 allele and Alzheimer's disease is accepted, the magnitude of the APOE associated risk for Alzheimer's disease is epidemiologically significant. It has been claimed that about 10% to 40% of all cases of Alzheimer's disease are due to the effect of the e4 allele,475254101 Hence such a proportion of cases might be spared if the risk factor should be eliminated. This has relevant implications for public health,'02 and research into the therapeutic issues of APOE continues. Alzheimer's disease e4 carriers might be differentially responsive to therapy with cognitive enhancers'03 104 and the biology of the E4 isoform in the brain is being investigated with the aim of finding drugs that might counteract its effects. [105] [106] [107] It seems likely that sometime in the future APOE genotyping might be used in screening programmes to select asymptomatic E4 carriers for primary prophylaxis'02 or to increase the sensitivity of epidemiological case finding tools'08 aimed at detecting early Alzheimer's disease for secondary prophylaxis.'09110
The clinical applications of genetic testing in dementia are still in their preliminary stages. The search for the known defects can be useful in a limited number of cases, but prediction of age of onset in mutation carriers, even when positive, is fraught with great uncertainty. The e4 allele of APOE is an established risk factor for Alzheimer's disease, accounting for 10%-40% of all the cases, but its usefulness as a diagnostic test for Alzheimer's disease must be confirmed, and its role as a screening tool in populations must be assessed in future studies. There is also a need to compute reliable estimates of the age specific risk for Alzheimer's disease associated with the E4/e4 and e4/-genotypes. To be clinically useful, genetic research work in dementia will need to shift from the one gene, one disease theory towards the quantitative trait model to provide estimates of the amount of clinical variability that can be accounted for by genetic factors.
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